Biomarker development for myasthenia gravis

about

Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker.How clinical trials of myasthenia gravis can inform pre-clinical drug development Circulating microRNAs as potential biomarkers in myasthenia gravis patients.

P2860

Q34393904-346B8246-4376-417E-99FC-F96E185B97AB Q35738870-C3FF976D-9F30-4CAB-A2A7-C3BFD041990B Q50073076-24666D9B-C404-4A6C-8094-947A7BF56D30

P2860

Biomarker development for myasthenia gravis

Item

http://www.wikidata.org/entity/Q36515375

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Biomarker development for myasthenia gravis

@ast

Biomarker development for myasthenia gravis

@en

type

Item

label

Biomarker development for myasthenia gravis

@ast

Biomarker development for myasthenia gravis

@en

prefLabel

Biomarker development for myasthenia gravis

@ast

Biomarker development for myasthenia gravis

@en

P1476

Biomarker development for myasthenia gravis

@en

P2093

Gary Cutter

http://www.w3.org/2001/XMLSchema#string

Gil I Wolfe

http://www.w3.org/2001/XMLSchema#string

Greg Minisman

http://www.w3.org/2001/XMLSchema#string

Henry J Kaminski

http://www.w3.org/2001/XMLSchema#string

Inmaculada Aban

http://www.w3.org/2001/XMLSchema#string

Robin Conwit

http://www.w3.org/2001/XMLSchema#string

P2860

Myasthenia gravis: past, present, and future

How to improve R&D productivity: the pharmaceutical industry's grand challenge

Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.

Animal models of myasthenia gravis.

Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis.

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.

Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies

P304

101-106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1749-6632.2012.06787.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

1275

http://www.w3.org/2001/XMLSchema#string

P50

Linda Kusner

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234030205

http://www.w3.org/2001/XMLSchema#string

P698

23278584

http://www.w3.org/2001/XMLSchema#string

P921

myasthenia gravis

biomarker

P932

3539232

http://www.w3.org/2001/XMLSchema#string

Biomarker development for myasthenia gravis

about

P2860

P2860

Biomarker development for myasthenia gravis

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P921

P932